Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

2.1K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

2.3K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.3K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.2K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
The Placebo Effect01:54

The Placebo Effect

5.9K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
5.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.

Drugs of today (Barcelona, Spain : 1998)·2016
Same author

Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

Drugs of today (Barcelona, Spain : 1998)·2016
Same author

Bupivacaine liposome injectable suspension: a new approach to postsurgical pain.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

Inhaled loxapine: a new treatment for agitation in schizophrenia or bipolar disorder.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures.

Drugs of today (Barcelona, Spain : 1998)·2013
Same author

The use of clobazam as an adjunctive treatment for Lennox-Gastaut syndrome.

Drugs of today (Barcelona, Spain : 1998)·2012

Related Experiment Video

Updated: May 3, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

220

Folate augmentation of antidepressant response.

R T Owen1

  • 1Freelance Medical Writer. scientific.prous@thomsonreuters.com.

Drugs of Today (Barcelona, Spain : 1998)
|February 14, 2014
PubMed
Summary
This summary is machine-generated.

Combining antidepressants shows promise for major depressive disorder treatment. Folate augmentation, particularly L-methylfolate, may enhance antidepressant response and remission rates with a good safety profile.

Keywords:
DepressionFolateL-Methylfolate

More Related Videos

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Related Experiment Videos

Last Updated: May 3, 2026

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression
12:43

Robotically Delivered fMRI-Guided Personalized Transcranial Magnetic Stimulation Therapy for Treatment-Resistant Depression

Published on: April 10, 2026

220
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.2K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Area of Science:

  • Psychiatry and Pharmacology
  • Neuroscience
  • Clinical Therapeutics

Background:

  • Major depressive disorder (MDD) pharmacotherapy is evolving, with combination antidepressant therapy emerging as a new paradigm.
  • Existing research presents mixed findings on the efficacy of initiating treatment with two antidepressants versus monotherapy.
  • Folate preparations have demonstrated potential as adjunctive treatments for augmenting antidepressant response.

Purpose of the Study:

  • To investigate the efficacy and safety of combination antidepressant therapy in major depressive disorder.
  • To evaluate the role of folate preparations, specifically L-methylfolate, as an augmentation strategy in MDD treatment.
  • To assess whether folate augmentation improves response and remission rates in patients with normal or low folate levels.

Main Methods:

  • Review of recent clinical trials examining combination antidepressant therapy for MDD.
  • Analysis of studies investigating folate preparations (folic acid, folinic acid, L-methylfolate) as augmentation agents.
  • Assessment of controlled and open-label studies in patients with varying folate statuses.

Main Results:

  • Some trials suggest improved response and remission rates with combination antidepressant therapy compared to monotherapy.
  • Folate preparations, including L-methylfolate, have shown effectiveness in augmenting antidepressant response.
  • L-methylfolate, the active form of folic acid, demonstrated promising adjunctive use with a favorable safety profile.

Conclusions:

  • Combination antidepressant therapy represents a potential shift in MDD pharmacotherapy.
  • L-methylfolate augmentation may be a beneficial strategy for enhancing treatment outcomes in major depressive disorder.
  • Further research is warranted to fully establish the role of combination therapy and folate augmentation in MDD management.